Abstract Number: 729 • 2015 ACR/ARHP Annual Meeting
The Effect of Belimumab on Peripheral Blood Cells in Patients with Systemic Lupus Erythematosus
Background/Purpose: The anti-BAFF antibody belimumab is the first biologic drug approved for treatment of mild-moderate SLE. While the efficacy of belimumab for this indication is…Abstract Number: 730 • 2015 ACR/ARHP Annual Meeting
Early Symptoms of Systemic Lupus Erythematosus As Reported By Members of the German Lupus Erythematosus Patient Association
Background/Purpose: EULAR and ACR have jointly funded a project to develop systemic lupus erythematosus (SLE) classification criteria, aiming at earlier and more accurate classification of…Abstract Number: 731 • 2015 ACR/ARHP Annual Meeting
Damage and Mortality in SLE: Cluster Analysis of Patients from SLE Registry from the Spanish Society for Rheumatology (RELESSER)
Background/Purpose: Damage in SLE is associated with mortality. Not every damage manifestation is associated in the same way. Some studies were made assessing this relation…Abstract Number: 732 • 2015 ACR/ARHP Annual Meeting
Decreased Disease Activity and Corticosteroid Usage and Improved Quality of Life during Belimumab Treatment in Patients with Systemic Lupus Erythematosus – a Prospective Real-Life Observational Study
Background/Purpose: Belimumab is the first biologic drug approved to treat Systemic Lupus Erythematosus (SLE). The efficacy of belimumab has been demonstrated through 2 phase III…Abstract Number: 733 • 2015 ACR/ARHP Annual Meeting
Late Onset Systemic Lupus Erythematosus: A Different Disease Subset?
Background/Purpose: To describe the demographic, clinical and immunological manifestations in patients with late onset systemic lupus erythematosus (SLE) Methods: Patients diagnosed of SLE in the RELESSER data…Abstract Number: 734 • 2015 ACR/ARHP Annual Meeting
Disease Patterns, Flare Incidence and Organ Damage Among Filipino Patients with Systemic Lupus Erythematosus: a One-Year Observational Study
Background/Purpose: This study describes the disease patterns, flare incidence, hospitalizations and causes of mortality in a cohort of Filipino patients with systemic lupus erythematosus (SLE),…Abstract Number: 735 • 2015 ACR/ARHP Annual Meeting
Belimumab Reduces the Frequency of Flares and Prevents Damage Progression in SLE Patients: Experience in a Clinical Practice Setting
Background/Purpose: To investigate the efficacy and safety of belimumab in patients affected with active systemic lupus erythematosus (SLE) refractory to standard therapy. Methods: Fifty-eight patients,…Abstract Number: 736 • 2015 ACR/ARHP Annual Meeting
Complement Activation As a Marker for Increased Thrombosis Risk in SLE Patients with Antiphospholipid Antibodies
Background/Purpose: We and others have suggested that complement activation can serve as an initiating signal that increases the thrombosis risk in SLE patients with antiphospholipid antibodies.…Abstract Number: 737 • 2015 ACR/ARHP Annual Meeting
A Paper Patient-Based Flare Study in SLE
ACR Abstract – A Paper Patient-Based Flare Study in Systemic Lupus Erythematosus (SLE) Isenberg D, Sturgess J, Allan E, Aranow C, Aringer M, Askanase A,…Abstract Number: 738 • 2015 ACR/ARHP Annual Meeting
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BCL-2 Inhibitor Venetoclax (ABT-199) in a Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus
Background/Purpose: Apoptosis is needed to eliminate auto-reactive T and B cells during immune responses; failure of elimination is important in development of systemic lupus erythematosus…Abstract Number: 739 • 2015 ACR/ARHP Annual Meeting
Prednisone Increases Both Arterial and Venous Thrombosis in SLE
Background/Purpose: An increasing number of studies have investigated factors that are associated with thrombosis in SLE. However, few have examined risk factors specific for venous…Abstract Number: 740 • 2015 ACR/ARHP Annual Meeting
The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus
Background/Purpose: Autoantibodies to the nuclear autoantigen dense fine speckles 70 (DFS70) are associated with a new paradigm whereby when they are found in isolation (monospecific…Abstract Number: 741 • 2015 ACR/ARHP Annual Meeting
Satisfaction and Impact Associated with the Addition of Belimumab to Systemic Lupus Erythematosus (SLE) Treatment: A Cross-Sectional Survey of US Rheumatologists and Their Patients
Background/Purpose: Patient and physician treatment satisfaction influences long-term adherence with a treatment regimen. The primary objective was to identify factors linked to satisfaction with the…Abstract Number: 742 • 2015 ACR/ARHP Annual Meeting
IgM Antibodies Against Malondialdehyde and Phosphorylcholine Are T Cell Dependent and Strong Protection Markers for Atherosclerosis in SLE
Background/Purpose: Atherosclerosis is characterized by activated immune competent cells and lipid oxidation, where two major epitopes forming adducts are phosphorylcholine (PC) and malondialdehyde (MDA).…Abstract Number: 743 • 2015 ACR/ARHP Annual Meeting
Behavior of Complement Levels and Risk of Organ Involvement in SLE Patients
Background/Purpose: the complement system plays a major role in autoimmune diseases, and in particular in systemic lupus erythematosus (SLE). Complement deficiencies are a genetic risk factor for SLE.…
ACR Meeting Abstracts